J&J taps into BARDA well a third time to speed up its PhIII Covid-19 vaccine trial
BARDA is pouring $454 million more into Johnson & Johnson’s Covid-19 vaccine efforts, as the pharma huffs and puffs to catch up with fast-moving frontrunners Pfizer/BioNTech and Moderna.
Janssen, the J&J subsidiary developing the vaccine candidate, has already received over $1.4 billion from the HHS department. Under the expanded agreement, BARDA will kick in another $454 million to support the company’s 60,000-person Phase III trial, and J&J will commit another $604 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.